PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.935 | 1.94% | 49.125 | 49.64 | 47.95 | 48.19 | 48.19 | 09:45:07 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 48.86 | 49.36 | 0.50 | 1.01% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 249 | 24,795 | $ 48.56 | $ 1,204,106 | 494,784 | 30.38 - 63.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:45:01 | 1 | $ 48.87 | USD |
REGENXBIO Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.81B | 36.87M | $ 99.94M | 2.84 | - | 36.36M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
REGENXBIO News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/16/2020 | 16:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/10/2020 | 16:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/09/2020 | 07:12 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/09/2020 | 07:00 | PR Newswire (US) | REGENXBIO Reports Continued Progress Across Programs in.. |
| 1/06/2020 | 16:26 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/06/2020 | 16:25 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/06/2020 | 16:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 43.62 | 50.09 | 42.695 | 47.82 | 465,933 | 5.51 | 12.62% |
| 1 Month | 41.68 | 50.09 | 37.76 | 43.06 | 444,138 | 7.45 | 17.86% |
| 3 Months | 41.00 | 50.09 | 34.02 | 40.91 | 492,060 | 8.13 | 19.82% |
| 6 Months | 49.59 | 54.9071 | 30.38 | 39.49 | 526,839 | -0.465 | -0.94% |
| 1 Year | 46.82 | 63.21 | 30.38 | 44.84 | 532,042 | 2.31 | 4.92% |
| 3 Years | 19.75 | 85.10 | 16.30 | 44.28 | 449,665 | 29.38 | 148.73% |
| 5 Years | 30.26 | 85.10 | 7.0701 | 40.50 | 361,836 | 18.87 | 62.34% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
